Ono Pharmaceutical (4528.T)

Executive Summary

Ono Pharmaceutical (TYO: 4528) is a Japan-based biopharmaceutical company with a strong focus on oncology, immunology, and neurology. The company boasts a substantial pipeline of 187 drug candidates, ranging from early-stage to late-stage development, and a commercial portfolio that includes globally recognized products such as Opdivo (nivolumab), developed in partnership with Bristol-Myers Squibb. Ono's strategy centers on addressing unmet medical needs through internal R&D and strategic alliances. Recent pipeline progress includes promising Phase 2 data for ONO-2808 in Multiple System Atrophy and Tirabrutinib in Primary CNS Lymphoma. With a market cap of approximately $6.5 billion, Ono is well-positioned to deliver near-term catalysts from key readouts and regulatory submissions, though execution risks remain in its mid-stage pipeline. The company's diversified approach and strong partnership network underpin its growth trajectory.

Upcoming Catalysts (preview)

• H2 2026Phase 2 results for ONO-2808 in Multiple System Atrophy50% success
• 2027Phase 2 results for Tirabrutinib in Primary CNS Lymphoma40% success
• Q1 2027Regulatory submission for Opdivo in a new indication in Japan70% success